BTG's BioTropin Approved In USA

4 June 1995

The US Food and Drug Administration has approved Israeli company Bio-Technology General's recombinant human growth hormone product BioTropin. It is indicated for the treatment of children with small stature. This is the first US approval of a BTG product, and is the latest development in a long battle to bring BioTropin to market.

In January, the US International Trade Commission dismissed a claim by competitor Genentech that BTG's product infringed some process patents. Another patent litigation in a US federal district court is still outstanding, but this will not prevent BTG launching the drug. The market for hGH products in the USA is around $300 million a year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight